Lilly was founded in 1876, with Headquarters located in Indianapolis, Indiana, U.S.A and with operations based in the US and EU, Eli Lilly is now the 10th largest pharmaceutical company in the world. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Eli Lilly is a research-based pharmaceutical company committed to create value for all stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients and to help people live longer, healthier, more active lives.  
Eli Lilly employs approximately 38,000 people worldwide. Approximately 7,400 employees are engaged in research and development. Clinical research is being conducted in more than 55 countries, with research and development facilities located in 8 countries and manufacturing plants located in 13 countries. Lilly products are marketed in 125 countries.
Eli Lilly and Company has broad interest in Oncology with several marketed products in pancreatic, lung and colorectal cancer. Oncology drug development is focused on new medicines tailored for the most responsive patient population and has active biomarker research for most of the current pipeline projects. Eli Lilly and Company has developed deep expertise in next generation sequencing technologies in order to better understand molecular changes in cancer. The identification of clinically meaningful molecular subtypes and associated matching model systems is tightly linked to our biomarker discovery. A special interest in biomarker research is focused on liquid biopsies which could present a safer and more informative alternative to current tumour biopsies.